אינטגרילין 2 מגמל

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

EPTIFIBATIDE

Available from:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

ATC code:

B01AC16

Pharmaceutical form:

תמיסה להזרקה

Composition:

EPTIFIBATIDE 2 MG/ML

Administration route:

תוך-ורידי

Prescription type:

מרשם נדרש

Manufactured by:

SCHERING-PLOUGH LABO. N.V , BELGIUM

Therapeutic group:

EPTIFIBATIDE

Therapeutic area:

EPTIFIBATIDE

Therapeutic indications:

Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.

Authorization date:

2013-10-31